Clovis Oncology (NASDAQ:CLVS) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Friday.
Several other equities analysts have also weighed in on the stock. Credit Suisse Group set a $86.00 price objective on shares of Clovis Oncology and gave the company a “buy” rating in a report on Thursday. They noted that the move was a valuation call. ValuEngine upgraded shares of Clovis Oncology from a “sell” rating to a “hold” rating in a report on Friday, December 29th. Zacks Investment Research lowered shares of Clovis Oncology from a “hold” rating to a “sell” rating in a report on Tuesday, January 16th. Oppenheimer reiterated a “hold” rating on shares of Clovis Oncology in a report on Tuesday, October 10th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Clovis Oncology in a report on Thursday, January 11th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $90.43.
Shares of Clovis Oncology (NASDAQ:CLVS) traded up $0.89 on Friday, reaching $56.76. 836,842 shares of the company’s stock were exchanged, compared to its average volume of 1,250,000. The company has a quick ratio of 3.16, a current ratio of 3.19 and a debt-to-equity ratio of 0.94. The company has a market capitalization of $2,780.00, a PE ratio of -6.86 and a beta of 1.38. Clovis Oncology has a twelve month low of $45.42 and a twelve month high of $99.45.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $59.16, for a total value of $177,480.00. Following the completion of the sale, the insider now owns 183,571 shares in the company, valued at approximately $10,860,060.36. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Thorlef Spickschen sold 4,500 shares of the stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $64.97, for a total transaction of $292,365.00. Following the completion of the sale, the director now owns 21,118 shares of the company’s stock, valued at approximately $1,372,036.46. The disclosure for this sale can be found here. Insiders sold a total of 18,000 shares of company stock worth $1,123,425 in the last 90 days. 12.50% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of CLVS. Capital Analysts LLC purchased a new stake in Clovis Oncology in the 3rd quarter valued at about $111,000. Phocas Financial Corp. purchased a new stake in Clovis Oncology in the 2nd quarter valued at about $112,000. Cypress Capital Management LLC WY increased its stake in Clovis Oncology by 272.7% in the 3rd quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 1,500 shares during the last quarter. Commonwealth Equity Services Inc purchased a new stake in Clovis Oncology in the 3rd quarter valued at about $239,000. Finally, First Republic Investment Management Inc. purchased a new stake in Clovis Oncology in the 3rd quarter valued at about $251,000.
WARNING: This report was posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/21/bidaskclub-lowers-clovis-oncology-clvs-to-strong-sell.html.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.